查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1950465

遗传性血管性水肿 (HAE) 治疗市场按适应症、药物类别、给药途径、分销管道和患者年龄组划分，全球预测，2026-2032 年

Drugs for HAE Market by Indication Type, Drug Class, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，遗传性血管性水肿 (HAE) 治疗市场价值将达到 37.5 亿美元，到 2026 年将成长至 42.9 亿美元，到 2032 年将达到 84.2 亿美元，复合年增长率为 12.24%。

关键市场统计数据
基准年 2025 37.5亿美元
预计年份：2026年 42.9亿美元
预测年份 2032 84.2亿美元
复合年增长率 (%) 12.24%

这是一份简明的临床和治疗指南，概述了遗传性血管性水肿的病理生理学、治疗类别以及不断变化的患者照护重点。

遗传性血管性水肿（HAE）是一种罕见的遗传性疾病，其特征是阵发性、非搔痒性肿胀，由激肽释放酶-激肽系统失调和血管活性肽缓激肽过度生成引起。临床上，它表现为不可预测的发作，涉及四肢、脸部、呼吸道和胃肠道，既可导致危及生命的急性病症，也可造成慢性生活品质负担。其病理生理机转主要集中在C1酯酶抑制剂的数量或功能缺陷，或激肽释放酶活性调节成分的特定缺陷，这些因素共同促进缓激肽介导的血管渗透性增加。

科学创新、不断发展的医疗服务模式以及支付方对实际疗效的关注，正在如何重塑遗传性血管性水肿的治疗方案和诊疗路径？

遗传性血管性水肿 (HAE) 的治疗格局正经历着一场变革性的转变，这主要得益于科学进步、病患偏好以及医疗服务模式的转变。在分子层面，单株抗体和口服小分子药物的创新，拓展了治疗选择，使其超越了传统的血浆衍生疗法，从而能够透过新的机制抑制激肽释放酶活性并选择性地抑制缓激肽讯号传导。技术进步也促成了重组 C1 抑制剂和皮下製剂的研发，降低了给药的复杂性，支持居家治疗，减少了预防性治疗的门槛，并提高了治疗的连续性。

评估近期美国关税变化对 HAE 治疗供应链、价格趋势和策略采购方式的影响

美国2025年实施的新关税对HAE的供应链、定价策略以及活性成分和成品生技药品的跨境采购产生了多方面的影响。依赖国际原料采购和契约製造组织的製造商由于新增关税和合规要求，其成本结构发生了变化，导致部分製造商重新调整供应商结构，并考虑垂直整合和增加近岸外包。低温运输物流，尤其是生物製药，成本高昂且对前置作业时间要求严格，这加剧了关税相关行政流程对营运的影响，并加重了进口商和经销商的行政负担。

综合細項分析揭示了适应症、治疗方法、给药途径、分销管道和年龄组如何影响临床和商业性决策。

关键的市场细分洞察凸显了临床创新、准入途径和商业策略在适应症类型、药物类别、给药途径、分销管道和患者群体特征方面的交汇点。从适应症角度来看，治疗方案主要分为两大类：急性治疗和长期预防性治疗。急性治疗方案包括能够快速抑制持续性缓激肽介导的肿胀的药物，例如缓激肽受体拮抗剂、C1抑制剂和激肽释放酶抑制剂。在C1抑制剂类别中，血浆来源产品和重组产品各自发挥不同的临床和物流作用，而激肽释放酶抑制剂则以单株抗体或口服小分子药物的形式存在。长期预防治疗同样可分为以C1抑制剂为基础的疗法和激肽释放酶抑制策略。每个子类别在作用持续时间、给药频率和监测要求方面各有优劣，血浆来源产品和重组产品，或单株抗体和小分子药物，可根据不同的患者和医疗服务提供者的偏好进行选择。

区域比较概览，概述了监管、报销和基础设施方面的区域差异如何导致世界各地准入策略的差异

区域趋势对遗传性血管性水肿药物的可及性、监管时间表和应用模式有显着影响，因此，制定全球策略时必须采取细緻入微的视角。在美洲，完善的临床试验网络、成熟的专科药房基础设施以及支付方的深入了解，使得新型生物製药和口服药物能够相对快速地引入市场，但报销谈判和事先核准流程可能会限制某些临床环境下的药物应用。製造商通常会优先考虑该地区的上市顺序，并建立全面的患者支援体系，包括宅配服务和输液培训。

企业策略以及在製造、证据生成和患者服务方面的能力投资如何塑造遗传性血管性水肿治疗领域的竞争优势

在HAE领域，企业策略体现了在维持现有生物製药业务与投资下一代治疗方法之间的平衡，这些疗法有望带来更便捷的使用体验或差异化的作用机制。大型生物製药公司凭藉其成熟的生产能力、与临床医生的良好关係以及分销网络，在急诊和预防性治疗领域保持着稳固的地位。同时，新兴生技公司则优先发展单株抗体、小分子药物和重组蛋白，以获得独特的临床优势。成熟生产商与小规模创新企业之间的合作日益普遍，这使他们能够加速临床开发、扩大生产能力并分担商业化责任。

製造商和相关人员可以采取哪些切实可行的策略行动来确保供应的稳定性，展现差异化价值，并改善HAE治疗的病患疗效？

为了在不断发展的遗传性血管性水肿（HAE）领域中获取临床和商业性价值，产业领导者应采取以韧性、差异化和以患者为中心为核心的综合策略行动。首先，采购和製造地的多元化将降低受区域关税波动和供应中断的影响。将关键生物製药的生产转移到邻近地区并确保多家原料药供应商，将有助于提高生产的连续性。其次，为了扩大预防性治疗的覆盖范围并提高患者依从性，企业应优先开发和商业化便于患者使用的製剂，例如皮下和口服给药途径，同时投资积累可靠的儿童证据，以支持扩大适应症。

调查方法概述：此方法整合临床、监管、专家和供应链证据，为相关人员提供可操作的见解。

本分析整合了临床文献、监管申报文件、临床试验註册资讯、专家访谈和供应链评估等证据，从多观点呈现了遗传性血管性水肿（HAE）的治疗现状。主要资讯来源包括对免疫学和过敏科临床医生、熟悉专科药物分销的药房部门负责人以及熟悉罕见病报销框架的支付方代表的结构化访谈。二级资讯来源包括关于病理学和疗效比较的同行评审研究、监管核准文件以及已发布的罕见疾病管理指南，以综合解读临床和政策讯号。

总结而言，协作创新、证据生成和运作韧性如何将治疗进展转化为患者照护的持续改善。

遗传性血管性水肿 (HAE) 治疗领域正处于一个转折点，生物製药创新、便捷的给药方式以及不断变化的支付方期望在此交汇，既带来了新的机会，也带来了运营挑战。临床进展催生了更具针对性的预防和治疗机制，而给药方式的进步则改善了患者在医疗机构外获得预防性护理的机会。同时，包括贸易政策调整、日益复杂的报销流程以及地域覆盖不均在内的外部压力，正迫使生产商和医疗服务提供者在生产、定价和循证医学证据收集方面采取更具战略性的策略。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依适应症分類的遗传性血管性水肿 (HAE) 治疗市场

  • 急性治疗
    • 缓激肽受体拮抗剂
    • C1抑制剂
    • C1抑制剂
      • 血浆衍生产品
      • 重组
    • 激肽释放酶抑制剂
      • 单株抗体
      • 低分子化合物
  • 长期预防性治疗
    • C1抑制剂
      • 血浆衍生产品
      • 重组
    • 激肽释放酶抑制剂
      • 单株抗体
      • 低分子化合物

9. 遗传性血管性水肿 (HAE) 治疗药物市场（依药物类别划分）

  • 缓激肽受体拮抗剂
  • C1抑制剂
    • 血浆衍生
    • 重组
  • 激肽释放酶抑制剂
    • 单株抗体
    • 低分子化合物

10. 遗传性血管性水肿 (HAE) 治疗药物市场（依给药途径划分）

  • 静脉注射
  • 口服
  • 皮下注射

第十一章 遗传性血管性水肿 (HAE) 治疗市场（依分销管道划分）

  • 医院药房
  • 零售药房
  • 专科药房

第十二章：按患者年龄层分類的遗传性血管性水肿 (HAE) 治疗市场

  • 成人
  • 儿童

13. 各地区遗传性血管性水肿 (HAE) 治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 遗传性血管性水肿 (HAE) 治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 遗传性血管性水肿 (HAE) 治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国遗传性血管性水肿（HAE）治疗市场：

第十七章：中国遗传性血管性水肿（HAE）治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • ADARx Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Astria Therapeutics, Inc.
  • Attune Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.
  • BioMarin Pharmaceutical Inc.
  • CSL Behring LLC
  • Grifols, SA
  • Intellia Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • KalVista Pharmaceuticals, Inc.
  • Pharming Group NV
  • Pharvaris NV
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals Industries Ltd.
Product Code: MRR-4F7A6D4FD87F

The Drugs for HAE Market was valued at USD 3.75 billion in 2025 and is projected to grow to USD 4.29 billion in 2026, with a CAGR of 12.24%, reaching USD 8.42 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.75 billion
Estimated Year [2026] USD 4.29 billion
Forecast Year [2032] USD 8.42 billion
CAGR (%) 12.24%

A concise clinical and therapeutic primer capturing hereditary angioedema pathophysiology, treatment categories, and evolving patient care priorities

Hereditary angioedema (HAE) is a rare, genetically mediated disorder characterized by episodic, nonpruritic swelling resulting from dysregulation of the kallikrein-kinin system and excess generation of the vasoactive peptide bradykinin. Clinically, HAE manifests with unpredictable attacks that can involve the extremities, face, airway, and gastrointestinal tract, posing both acute life-threat scenarios and chronic burdens on quality of life. The pathophysiology centers on either quantitative or functional deficiency of C1 esterase inhibitor or on specific defects in components that regulate kallikrein activity, which together drive bradykinin-mediated increased vascular permeability.

Therapeutic approaches divide into therapies for acute attack management and strategies for long-term prophylaxis. Acute interventions aim to resolve established swelling by interrupting kallikrein activity, blocking bradykinin receptors, or replacing deficient inhibitors. Prophylactic regimens seek to reduce attack frequency and severity through intermittent or continuous modulation of the same biological pathways. Over the past decade, treatment options have diversified to include plasma-derived and recombinant biologicals, monoclonal antibodies targeting kallikrein, and small-molecule oral agents, enabling more personalized regimens for adults and pediatric patients. As clinical practice evolves, emphasis increasingly rests on rapid access to effective acute care, safe and convenient prophylactic options, and integrated patient support to improve adherence and reduce emergency care utilization.

How scientific innovation, delivery model evolution, and payer emphasis on real world outcomes are reshaping therapeutic choices and care pathways for hereditary angioedema

The HAE treatment landscape is undergoing transformative shifts driven by scientific advances, patient preferences, and changes in care delivery. At the molecular level, innovations in monoclonal antibodies and orally available small molecules have expanded the therapeutic toolkit beyond traditional plasma-derived products, enabling new mechanisms to suppress kallikrein activity and blunt bradykinin signaling with greater selectivity. Technological refinement has also produced recombinant C1 inhibitors and subcutaneous formulations that reduce administration complexity and support at-home therapy, thereby lowering barriers to prophylaxis and improving continuity of care.

Concurrently, payers and providers are emphasizing value and real-world evidence, shifting contracting approaches toward outcomes-based arrangements and tighter formulary management. Telehealth integration and specialty pharmacy partnerships have facilitated remote initiation and ongoing monitoring, which is particularly important for rare disease populations who may be geographically dispersed. Trial design has adapted in parallel, with adaptive protocols and patient-reported outcome measures becoming more prominent to capture meaningful improvements in daily functioning. Taken together, these dynamics are reshaping clinical decision making, accelerating uptake of convenient and durable therapies, and prompting manufacturers to prioritize patient support services, real-world data collection, and differentiated delivery models to maintain competitive advantage.

Assessment of how recent United States tariff shifts have affected HAE therapeutic supply chains, pricing dynamics, and strategic sourcing approaches

The introduction of new tariff measures in the United States in 2025 created a spectrum of downstream implications for the HAE supply chain, pricing strategies, and cross-border procurement of active pharmaceutical ingredients and finished biologics. Manufacturers that rely on international raw material sourcing or contract manufacturing organizations found cost structures affected by additional duties and compliance requirements, prompting some to reassess supplier footprints and to explore greater vertical integration or nearshoring. For biologics, in particular, the cost and lead time sensitivities associated with cold-chain logistics magnified the operational impact of tariff-related administrative processes, increasing the administrative burden on importers and distributors.

Payers and contracting teams responded by scrutinizing procurement pathways and emphasizing domestic manufacturing where feasible to mitigate future policy volatility. Specialty pharmacies and hospital systems evaluated formulary implications and inventory strategies to ensure uninterrupted access for patients reliant on prophylactic regimens and on-demand therapies. Manufacturers adopted several mitigation tactics, including renegotiating supplier terms, diversifying API sources, and absorbing portions of tariff costs for flagship products to preserve clinical uptake and adherence. In parallel, regulatory engagement increased as stakeholders sought clarity on classification and duty codes for novel biologics and combination products to avoid inadvertent tariff exposure. These combined actions underscore the importance of supply chain resilience and policy foresight in sustaining access to HAE therapies amid shifting trade landscapes.

Integrated segmentation analysis revealing how indication, modality, administration route, distribution channel, and age demographics determine clinical and commercial decision making

Key segmentation insights illuminate where clinical innovation, access pathways, and commercial strategy intersect across indication types, drug classes, administration routes, distribution channels, and patient age groups. When the market is viewed through the lens of indication, therapeutic choices fall into two principal categories: acute treatment and long-term prophylaxis. Acute treatment options encompass agents that act rapidly to halt ongoing bradykinin-mediated swelling and include bradykinin receptor antagonists, C1 inhibitors, and kallikrein inhibitors; within the C1 inhibitors category, both plasma-derived and recombinant products play distinct clinical and logistical roles, while kallikrein inhibitors appear as monoclonal antibodies or as orally administered small molecules. Long-term prophylaxis similarly segments into C1 inhibitor-based approaches and kallikrein inhibition strategies, with each subcategory offering tradeoffs between durability of effect, administration frequency, and monitoring requirements, and with plasma-derived and recombinant formats or monoclonal and small-molecule chemistries catering to different patient and provider preferences.

Analyzing drug class segmentation reinforces the importance of modality on clinical decision making, as bradykinin receptor antagonists provide acute-phase pathway blockade whereas C1 inhibitors and kallikrein inhibitors offer both acute and prophylactic utility depending on formulation and dosing. Route of administration segmentation-spanning intravenous, oral, and subcutaneous delivery-clarifies the growing preference among patients and clinicians for convenient, self-administered modalities that reduce emergency department dependence and support adherence. Distribution channel considerations-hospital pharmacy, retail pharmacy, and specialty pharmacy-highlight variance in access pathways, with specialty pharmacies playing a pivotal role in patient education, reimbursement coordination, and home delivery, while hospital settings remain critical for acute care and intravenous administration. Finally, patient age group segmentation into adult and pediatric populations underscores distinct safety, dosing, and formulation needs, and the necessity of pediatric-specific evidence to support early intervention strategies and age-appropriate administration formats. Integrating these segmentation lenses enables a more granular approach to clinical trial design, commercial positioning, and patient support program development.

Comparative regional overview outlining how local regulatory, reimbursement, and infrastructure differences drive differentiated access strategies across global territories

Regional dynamics materially affect access, regulatory timelines, and adoption patterns for hereditary angioedema therapies, and a nuanced view is essential for global strategy. In the Americas, robust clinical trial networks, established specialty pharmacy infrastructure, and payer sophistication enable relatively rapid adoption of novel biologics and oral agents, although reimbursement negotiations and prior authorization processes can moderate uptake in certain care settings. Manufacturers often prioritize the region for launch sequencing and for building comprehensive patient support offerings that include home delivery and infusion training.

In Europe, Middle East & Africa, reimbursement variability across national systems shapes commercialization approaches; centralized approvals at supranational levels coexist with country-level health technology assessments that assess comparative effectiveness and budget impact. Procurement models and tendering practices in parts of the region can favor established suppliers or lower-cost alternatives, making evidence generation and pricing strategies critical. Regulatory harmonization efforts and greater engagement with regional patient advocacy groups are increasingly influential in improving access.

In the Asia-Pacific region, heterogeneity spans mature markets with advanced regulatory pathways and emerging markets with infrastructural constraints. Emerging economies place a high premium on affordability and local manufacturing partnerships, while advanced markets emphasize real-world evidence and alignment with regional clinical guidelines. Across the region, expanding clinical trial activity and growing specialist capacity present opportunities for scaled registries and post-marketing data collection to support long-term safety and comparative effectiveness assessments. Strategic regional differentiation in manufacturing, pricing, and evidence generation is therefore central to successful, equitable access.

How corporate strategies and capability investments in manufacturing, evidence generation, and patient services shape competitive advantage within hereditary angioedema therapeutics

Company strategies in the HAE space reflect a balance between sustaining legacy biologic franchises and investing in next-generation modalities that promise improved convenience and differentiated mechanisms of action. Large biopharmaceutical companies leverage established manufacturing capabilities, clinician relationships, and distribution networks to maintain presence in acute and prophylactic segments, while emerging biotechnology firms prioritize nimble development of monoclonal antibodies, small molecules, and recombinant proteins to capture niche clinical advantages. Partnerships between incumbent manufacturers and smaller innovators have become common, enabling accelerated clinical development, expanded manufacturing capacity, and shared commercialization responsibilities.

Across the industry, emphasis on differentiated patient services has become a competitive axis, with successful companies integrating education, adherence support, and reimbursement navigation into their go-to-market models. Investment in cold-chain logistics and biologics manufacturing scale is particularly important for companies supplying plasma-derived or recombinant C1 inhibitors, while developers of oral kallikrein inhibitors focus on establishing strong safety datasets and ease-of-use messaging. Corporate strategies also include targeted labeling expansions for pediatric populations and lifecycle management through novel formulations or delivery systems. Overall, capability in evidence generation, manufacturing resiliency, and payer engagement distinguishes market leaders from smaller entrants seeking to displace incumbents via clinical differentiation or cost advantages.

Practical strategic actions that manufacturers and stakeholders can implement to secure supply resilience, demonstrate differentiated value, and improve patient outcomes in HAE care

To capture clinical and commercial value in the evolving HAE landscape, industry leaders should adopt an integrated set of strategic actions focused on resilience, differentiation, and patient centricity. First, diversify sourcing and manufacturing footprints to reduce exposure to regional tariff shifts and supply interruptions; nearshoring critical biologics production and securing multiple API suppliers will improve continuity. Second, prioritize development and commercialization of patient-friendly formulations-such as subcutaneous or oral options-to expand prophylaxis uptake and improve adherence, while concurrently investing in robust pediatric evidence to support broader labeling.

Third, strengthen relationships with specialty pharmacies and expand digital patient support platforms that combine education, adherence reminders, and remote monitoring to reduce acute care reliance and demonstrate real-world value. Fourth, engage early and proactively with payers and health technology assessment bodies to align clinical trial endpoints with payer expectations and to explore outcomes-based contracting where appropriate. Fifth, invest in post-market safety and effectiveness studies and in registries that capture long-term outcomes across diverse patient populations, thereby reinforcing value propositions. Finally, incorporate scenario planning for trade and regulatory shifts into commercial forecasts and pricing strategies, ensuring agility in contracting and the ability to respond to policy changes without disrupting patient access. Together, these actions position companies to deliver clinically meaningful advances while safeguarding supply and commercial viability.

Methodology overview describing how clinical, regulatory, expert, and supply chain evidence were synthesized to generate actionable insights for stakeholders

This analysis synthesizes evidence from clinical literature, regulatory filings, trial registries, expert consultations, and supply chain assessments to provide a multidimensional view of the HAE therapeutic environment. Primary inputs included structured interviews with clinicians specializing in immunology and allergy, pharmacy leaders experienced in specialty product distribution, and payer representatives familiar with rare disease reimbursement frameworks. Secondary sources encompassed peer-reviewed studies on pathophysiology and comparative efficacy, regulatory approval documents, and published guidance on rare disease management to triangulate clinical and policy signals.

Supply chain and tariff impact assessments combined customs and trade classification analysis with stakeholder reporting from manufacturers and distributors to evaluate operational implications. Competitive and company capability insights were derived from public disclosures, pipeline tracking, and synthesis of partnership and licensing activity. Where relevant, patient advocacy perspectives were included to capture real-world access barriers and priorities. Throughout, methodological rigor was maintained via cross-validation of inputs, explicit documentation of assumptions, and transparent acknowledgment of data limitations, particularly where proprietary commercial terms or unpublished trial datasets were not accessible. This layered approach ensures balanced, actionable conclusions while recognizing the evolving nature of clinical evidence and policy environments.

Concluding perspective on how coordinated innovation, evidence generation, and operational resilience can convert therapeutic advances into sustained improvements in patient care

The hereditary angioedema therapeutic arena is at an inflection point where biologic innovation, convenient administration formats, and evolving payer expectations intersect to create new opportunities and operational challenges. Clinical progress has yielded more targeted mechanisms to prevent and treat attacks, and advancements in delivery have made prophylaxis more accessible outside institutional settings. At the same time, external pressures such as trade policy adjustments, reimbursement complexity, and regional heterogeneity in access require manufacturers and care providers to be more strategic about manufacturing, pricing, and evidence generation.

Looking ahead, stakeholders who align product development with patient preferences, invest in resilient supply chains, and build robust real-world evidence frameworks will be best positioned to deliver meaningful clinical benefits while sustaining commercial viability. Collaboration across manufacturers, specialty pharmacies, and payers to streamline access and to demonstrate outcomes in routine practice will be essential for translating therapeutic advances into better patient experiences and reduced acute care burden. In sum, coordinated, evidence-driven action is required to ensure that innovation in HAE therapy translates into durable improvements in patient health and health system efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drugs for HAE Market, by Indication Type

  • 8.1. Acute Treatment
    • 8.1.1. Bradykinin Receptor Antagonists
    • 8.1.2. C1 Inhibitors
    • 8.1.3. C1 Inhibitors
      • 8.1.3.1. Plasma Derived
      • 8.1.3.2. Recombinant
    • 8.1.4. Kallikrein Inhibitors
      • 8.1.4.1. Monoclonal
      • 8.1.4.2. Small Molecule
  • 8.2. Long Term Prophylaxis
    • 8.2.1. C1 Inhibitors
      • 8.2.1.1. Plasma Derived
      • 8.2.1.2. Recombinant
    • 8.2.2. Kallikrein Inhibitors
      • 8.2.2.1. Monoclonal
      • 8.2.2.2. Small Molecule

9. Drugs for HAE Market, by Drug Class

  • 9.1. Bradykinin Receptor Antagonists
  • 9.2. C1 Inhibitors
    • 9.2.1. Plasma Derived
    • 9.2.2. Recombinant
  • 9.3. Kallikrein Inhibitors
    • 9.3.1. Monoclonal
    • 9.3.2. Small Molecule

10. Drugs for HAE Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Drugs for HAE Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Retail Pharmacy
  • 11.3. Specialty Pharmacy

12. Drugs for HAE Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Pediatric

13. Drugs for HAE Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drugs for HAE Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drugs for HAE Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drugs for HAE Market

17. China Drugs for HAE Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ADARx Pharmaceuticals, Inc.
  • 18.6. Arrowhead Pharmaceuticals, Inc.
  • 18.7. Astria Therapeutics, Inc.
  • 18.8. Attune Pharmaceuticals, Inc.
  • 18.9. BioCryst Pharmaceuticals, Inc.
  • 18.10. BioMarin Pharmaceutical Inc.
  • 18.11. CSL Behring LLC
  • 18.12. Grifols, S.A.
  • 18.13. Intellia Therapeutics, Inc.
  • 18.14. Ionis Pharmaceuticals, Inc.
  • 18.15. KalVista Pharmaceuticals, Inc.
  • 18.16. Pharming Group N.V.
  • 18.17. Pharvaris N.V.
  • 18.18. Regeneron Pharmaceuticals, Inc.
  • 18.19. Sanofi S.A.
  • 18.20. Swedish Orphan Biovitrum AB
  • 18.21. Takeda Pharmaceutical Company Limited
  • 18.22. Teva Pharmaceuticals Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUGS FOR HAE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUGS FOR HAE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUGS FOR HAE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUGS FOR HAE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUGS FOR HAE MARKET SIZE, BY BRADYKININ RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUGS FOR HAE MARKET SIZE, BY MONOCLONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUGS FOR HAE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUGS FOR HAE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUGS FOR HAE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUGS FOR HAE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUGS FOR HAE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUGS FOR HAE MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUGS FOR HAE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUGS FOR HAE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUGS FOR HAE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS DRUGS FOR HAE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL DRUGS FOR HAE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. GCC DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. GCC DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 239. GCC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 242. GCC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 243. GCC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. GCC DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. GCC DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. GCC DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 278. G7 DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. G7 DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. G7 DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 281. G7 DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 284. G7 DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. G7 DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 288. G7 DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 289. G7 DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. G7 DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 291. G7 DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 292. NATO DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 293. NATO DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 295. NATO DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 297. NATO DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 299. NATO DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 300. NATO DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 301. NATO DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 302. NATO DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 303. NATO DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. NATO DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 305. NATO DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 306. GLOBAL DRUGS FOR HAE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 317. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 318. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 319. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 320. UNITED STATES DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA DRUGS FOR HAE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA DRUGS FOR HAE MARKET SIZE, BY INDICATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA DRUGS FOR HAE MARKET SIZE, BY ACUTE TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 325. CHINA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 326. CHINA DRUGS FOR HAE MARKET SIZE, BY LONG TERM PROPHYLAXIS, 2018-2032 (USD MILLION)
  • TABLE 327. CHINA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 328. CHINA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 329. CHINA DRUGS FOR HAE MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 330. CHINA DRUGS FOR HAE MARKET SIZE, BY C1 INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 331. CHINA DRUGS FOR HAE MARKET SIZE, BY KALLIKREIN INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 332. CHINA DRUGS FOR HAE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 333. CHINA DRUGS FOR HAE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 334. CHINA DRUGS FOR HAE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)